{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:18:54Z","timestamp":1793215134974,"version":"4.5.0"},"reference-count":42,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Individuals with type 2 diabetes mellitus (T2DM) have an increased risk of cardiovascular disease. Arterial stiffness is an independent prognostic marker for cardiovascular disease development. We aimed at determining the effect of two different sodium-glucose co-transporter-2 (SGLT-2) inhibitors on ambulatory arterial stiffness in individuals with T2DM. Materials and Methods: In this single-center, single-arm, prospective study performed from January 2020 to August 2021, we planned to enroll adult subjects with T2DM and stable antidiabetic and antihypertensive treatment, assigned either to empagliflozin or dapagliflozin for 6 months. All eligible subjects underwent ambulatory blood pressure monitoring. We set as the primary efficacy outcome the change in ambulatory pulse wave velocity (PWV) from baseline to week 24. Results: We finally enrolled 46 diabetic subjects, with a mean age of 62.89 (8.53) years and mean T2DM duration of 9.72 (6.37) years. Thirty patients received dapagliflozin, while sixteen patients received empagliflozin. Due to COVID-19 pandemic restrictive measures during the study, the mean follow-up period extended from 6 months to 9.98 (3.27) months. Regarding the prespecified primary efficacy outcome, we found that the SGLT-2 inhibitor treatment did not have a significant effect on PWV (p = 0.65). Prior history of cardiovascular disease did not significantly affect the observed effects. Other indices of arterial stiffness, such as augmentation index and central pulse pressure, were not significantly affected, neither by empagliflozin nor by dapagliflozin. Conclusions: SGLT-2 inhibitor treatment with empagliflozin or dapagliflozin in subjects with T2DM failed to improve ambulatory PWV over a mean follow-up of 10 months. Registration number: ISRCTN88851713.<\/jats:p>","DOI":"10.3390\/medicina58091167","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T03:34:56Z","timestamp":1661744096000},"page":"1167","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study"],"prefix":"10.3390","volume":"58","author":[{"given":"Dimitrios","family":"Patoulias","sequence":"first","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine, General Hospital \u201cHippokration\u201d, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9643-9066","authenticated-orcid":false,"given":"Christodoulos","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Third Department of Cardiology, General Hospital \u201cHippokration\u201d, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Zografou","sequence":"additional","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine, General Hospital \u201cHippokration\u201d, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Katsimardou","sequence":"additional","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine, General Hospital \u201cHippokration\u201d, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asterios","family":"Karagiannis","sequence":"additional","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine, General Hospital \u201cHippokration\u201d, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine, General Hospital \u201cHippokration\u201d, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007\u20132017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00592-018-1253-5","article-title":"Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: A systematic review with trend analysis","volume":"56","author":"Vetrone","year":"2019","journal-title":"Acta Diabetol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","article-title":"Excess Mortality among Persons with Type 2 Diabetes","volume":"373","author":"Tancredi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jval.2017.12.019","article-title":"Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review","volume":"21","author":"Einarson","year":"2018","journal-title":"Value. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fca-2018-0045","article-title":"Type-2 diabetes mellitus and cardiovascular disease","volume":"14","author":"Henning","year":"2018","journal-title":"Future Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Jakubiak, G.K., Pawlas, N., Cie\u015blar, G., and Stanek, A. (2021). Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph182211970"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Jakubiak, G.K., Pawlas, N., Cie\u015blar, G., and Stanek, A. (2020). Chronic Lower Extremity Ischemia and Its Association with the Frailty Syndrome in Patients with Diabetes. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17249339"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jacc.2017.07.001","article-title":"Primary Prevention of Cardiovascular Disease in Diabetes Mellitus","volume":"70","author":"Newman","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacc.2009.10.061","article-title":"Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis","volume":"55","author":"Vlachopoulos","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacc.2013.09.063","article-title":"Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction","volume":"63","author":"Spears","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/0003319717742544","article-title":"Carotid-Femoral Pulse Wave Velocity in the Prediction of Cardiovascular Events and Mortality: An Updated Systematic Review and Meta-Analysis","volume":"69","author":"Zhong","year":"2018","journal-title":"Angiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/01.CIR.0000033824.02722.F7","article-title":"Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: An integrated index of vascular function?","volume":"106","author":"Cruickshank","year":"2002","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.2337\/dc13-0506","article-title":"Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: The Rio deJaneiro Type 2 Diabetes Cohort Study","volume":"36","author":"Cardoso","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jdiacomp.2016.06.008","article-title":"Aortic pulse wave velocity predicts incident cardiovascular events in patients with type 2 diabetes treated in primary care","volume":"30","author":"Wijkman","year":"2016","journal-title":"J. Diabetes Complicat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000499532","article-title":"Comparison of 24-hour and Office Pulse Wave Velocity for Prediction of Mortality in Hemodialysis Patients","volume":"49","author":"Matschkal","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000367791","article-title":"Evaluation of a Novel Brachial Cuff-Based Oscillometric Method for Estimating Central Systolic Pressure in Hemodialysis Patients","volume":"40","author":"Sarafidis","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41371-021-00606-4","article-title":"Ambulatory monitoring of central arterial pressure, wave reflections, and arterial stiffness in patients at cardiovascular risk","volume":"36","author":"Omboni","year":"2022","journal-title":"J. Hum. Hypertens"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review","volume":"72","author":"Zelniker","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/jch.13831","article-title":"Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors","volume":"22","author":"Patoulias","year":"2020","journal-title":"J. Clin. Hypertens"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., and Tentolouris, N. (2019). SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16162965"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.5114\/amsad.2022.116665","article-title":"Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: Does increase of hematocrit finally matter? Sub-analysis of a prospective, observational study","volume":"7","author":"Patoulias","year":"2022","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.117.029529","article-title":"Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus","volume":"136","author":"Striepe","year":"2017","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/HJH.0000000000001907","article-title":"Diabetic patients with essential hypertension treated with amlodipine: Blood pressure and arterial stiffness effects of canagliflozin or perindopril","volume":"37","author":"Ramirez","year":"2019","journal-title":"J. Hypertens"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/HJH.0000000000002690","article-title":"Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial","volume":"39","author":"Papadopoulou","year":"2021","journal-title":"J. Hypertens"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e015716","DOI":"10.1161\/JAHA.119.015716","article-title":"Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment","volume":"9","author":"Ikonomidis","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jch.13988","article-title":"Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study","volume":"22","author":"Kario","year":"2020","journal-title":"J. Clin. Hypertens."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1111\/jch.14079","article-title":"Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?","volume":"22","author":"Patoulias","year":"2020","journal-title":"J. Clin. Hypertens"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.medcli.2019.05.028","article-title":"Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus. Efecto de dapagliflozina sobre la rigidez arterial en pacientes con diabetes mellitus tipo 2","volume":"154","year":"2020","journal-title":"Med. Clin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7570\/jomes20040","article-title":"Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease","volume":"29","author":"Hong","year":"2020","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/aam.aam_19_20","article-title":"Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus","volume":"20","author":"Papazafiropoulou","year":"2021","journal-title":"Ann. Afr. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diab. Obes. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12933-017-0510-1","article-title":"A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation","volume":"16","author":"Ott","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/HJH.0000000000002480","article-title":"Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes","volume":"38","author":"Smits","year":"2020","journal-title":"J. Hypertens"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.2215\/CJN.03000315","article-title":"Arterial Stiffness and Decline in Kidney Function","volume":"10","author":"Sedaghat","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00592-020-01637-y","article-title":"Short-term impact of COVID-19 lockdown on metabolic control of patients with well-controlled type 2 diabetes: A single-centre observational study","volume":"58","author":"Biancalana","year":"2021","journal-title":"Acta. Diabetol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jacc.2010.12.017","article-title":"Aortic stiffness: Current understanding and future directions","volume":"57","author":"Cavalcante","year":"2011","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/9\/1167\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:18:58Z","timestamp":1760141938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/9\/1167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["medicina58091167"],"URL":"https:\/\/doi.org\/10.3390\/medicina58091167","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,27]]}}}